The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: recombinant viral vectorsBuy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Recombinant viral vectors is a key innovation area in the cell & gene therapy

Recombinant viral vectors are efficient vehicles with the ability to deliver a gene of choice  to target cells/tissue. Viral vectors are derived from different viruses and as such are characterised by different features. These vectors play a fundamental role in molecular biology research and are applicable in the field of gene therapy and vaccine development.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 210+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant viral vector-based medicinal preparations.

Key players in recombinant viral vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to recombinant viral vectors

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
C. H. Boehringer Sohn AG & Co KG 506 Unlock Company Profile
Bavarian Nordic AS 365 Unlock Company Profile
Merck & Co Inc 306 Unlock Company Profile
Johnson & Johnson 298 Unlock Company Profile
GSK plc 241 Unlock Company Profile
Centre National de la Recherche Scientifique 185 Unlock Company Profile
Etubics Corp 129 Unlock Company Profile
Pfizer Inc 116 Unlock Company Profile
Hookipa Pharma Inc 86 Unlock Company Profile
AlphaVax Inc 85 Unlock Company Profile
Precigen Inc 75 Unlock Company Profile
CareGroup Inc 69 Unlock Company Profile
Compagnie Merieux Alliance SAS 67 Unlock Company Profile
Sanofi 61 Unlock Company Profile
Otsuka Holdings Co Ltd 60 Unlock Company Profile
NantWorks LLC 54 Unlock Company Profile
Nant Holdings Ip, LLC 50 Unlock Company Profile
Altimmune Inc 49 Unlock Company Profile
Helmholtz Association of German Research Centres 46 Unlock Company Profile
Theravectys SA 45 Unlock Company Profile
Akamis Bio Ltd 41 Unlock Company Profile
Novartis AG 40 Unlock Company Profile
ViroNovative BV 36 Unlock Company Profile
Genelux Corp 34 Unlock Company Profile
Zoetis Inc 33 Unlock Company Profile
Gritstone Bio Inc 33 Unlock Company Profile
Vaxart Inc 32 Unlock Company Profile
Gilead Sciences Inc 31 Unlock Company Profile
Emergent BioSolutions Inc 31 Unlock Company Profile
Erasmus MC 31 Unlock Company Profile
Baxter International Inc 31 Unlock Company Profile
Intervet 27 Unlock Company Profile
International AIDS Vaccine Initiative 26 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 25 Unlock Company Profile
Nouscom AG 25 Unlock Company Profile
Takeda Pharmaceutical Co Ltd 24 Unlock Company Profile
Mayo Clinic 24 Unlock Company Profile
The United States Of America 23 Unlock Company Profile
GeoVax Labs Inc 22 Unlock Company Profile
City of Hope 22 Unlock Company Profile
NEW HOPE, CITY OF 21 Unlock Company Profile
Panacea Biotec Ltd 21 Unlock Company Profile
RegenxBio Inc 20 Unlock Company Profile
U.S. Department of Defence 19 Unlock Company Profile
CanSino Biologics Inc 18 Unlock Company Profile
AMVAC C.V. 18 Unlock Company Profile
American Gene Technologies International Inc 17 Unlock Company Profile
US Government 17 Unlock Company Profile
Profectus BioSciences Inc 16 Unlock Company Profile
I'rom Group Co Ltd 16 Unlock Company Profile

Source: GlobalData Patent Analytics

Merck is one of the leading patent filers in recombinant viral vector-based medicinal preparations. It is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. V-184, Lassa fever vaccine, LV-305, and MV-ZIKA are some of the recombinant vector vaccines, which are in clinical stages of development by Merck. Other leading patent filers in recombinant viral vectors include C. H. Boehringer Sohn and Bavarian Nordic.

In terms of application diversity, RegenxBio is the top company, followed by Akamis Bio and ViroNovative. By means of geographic reach, Vaxart holds the top position. Hookipa Pharma and Akamis Bio are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.